Drugs / Synthetic Tumor-Associated Peptide Vaccine Therapy
Synthetic Tumor-Associated Peptide Vaccine Therapy
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02600949 | May 2016 → May 2027 expected | colorectal adenocarcinoma, pancreatic ductal adenocarcinoma | M.D. Anderson Cancer Center | Enrolling by invitation | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Synthetic Tumor-Associated Peptide Vaccine Therapy | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02600949 ↗ |
| Modality | Vaccine | “personalized synthetic tumor-associated peptide vaccine therapy” NCT02600949 ↗ |
| Route | Subcutaneous | “Given SC” NCT02600949 ↗ |